Development, validation and application of an HPLC-MS/MS method for the determination of fentanyl and nor-fentanyl in human plasma and saliva.
Monitoring fentanyl concentration in saliva and plasma may be useful in pharmacokinetic/pharmacodynamic studies. Salivettes(®) have been used widely for collecting saliva samples. However due to its lipophilicity, fentanyl adsorbs to the cotton dental bud (CDB) used in this device. Furthermore, due to dry mouth being a common adverse effect seen in patients treated with opioids, obtaining enough saliva for analysis is often a challenge. Hence, a simple simultaneous method to quantify fentanyl and its metabolite in both human plasma and saliva was developed and validated. A novel extraction method was also developed and validated to recover fentanyl in saliva directly from the CDB. This extraction method utilises acetonitrile to recover the fentanyl directly from the CDB rather than recovery by centrifugation, which is not always possible. Reverse phase chromatographic separation was performed on a Shimadzu LC 20A HPLC system using gradient elution. The electrospray ion source (ESI) was operated in positive ion mode using an Applied Biosystems API 3200 LC/MS/MS as detector. Deuterated fentanyl (D5) and nor-fentanyl (D5) were used as internal standards (IS). The retention times for fentanyl and nor-fentanyl were 3.70 min and 3.20 min respectively. The lower limit of quantitation (LLOQ) was determined to be 0.030 μg/L in plasma and 0.045 in saliva for fentanyl and nor-fentanyl. Acceptable linearity for fentanyl and nor-fentanyl in both plasma and saliva was demonstrated from 0.02 to 10 μg/L (R(2) 0.9988-0.9994). Accuracy for fentanyl and nor-fentanyl in both plasma and saliva samples was between 96% and 108%. Total imprecision expressed as the co-efficient of variation was between 1.0 and 15.5% for both analytes in both matrices. The validated method was applied successfully in 11 paired plasma and saliva samples obtained from patients with cancer pain receiving transdermal fentanyl (Duragesic(®)) at doses from 25 μg to 100 μg.
School of Pharmacy, Gold Coast Campus, Griffith Health Institute, Griffith University, Qld 4222, Australia. Electronic address: srbista75@hotmail.com.
Sudeep R
SR
Bista
Mater Research Institute & Mater Pathology Services (Australian Centre for Paediatric Pharmacokinetics), South Brisbane, Qld 4101, Australia.
Michael
M
Lobb
School of Pharmacy, Gold Coast Campus, Griffith Health Institute, Griffith University, Qld 4222, Australia.
Alison
A
Haywood
Mater Research Institute & Mater Pathology Services (Australian Centre for Paediatric Pharmacokinetics), South Brisbane, Qld 4101, Australia.
Janet
J
Hardy
Mater Research Institute & Mater Pathology Services (Australian Centre for Paediatric Pharmacokinetics), South Brisbane, Qld 4101, Australia.
Angela
A
Tapuni
School of Pharmacy, Gold Coast Campus, Griffith Health Institute, Griffith University, Qld 4222, Australia; Mater Research Institute & Mater Pathology Services (Australian Centre for Paediatric Pharmacokinetics), South Brisbane, Qld 4101, Australia; School of Pharmacy, University of Queensland, St Lucia, Qld, Australia.
Ross
R
Norris
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring; D004355:Drug Stability; D005283:Fentanyl / Q000031:analogs & derivatives* / Q000032:analysis* / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D016014:Linear Models; D010146:Pain / Q000188:drug therapy; D015203:Reproducibility of Results; D012463:Saliva / Q000737:chemistry*; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*
C080127:norfentanyl; D005283:Fentanyl
Adsorption; Fentanyl; HPLC–MS/MS; Plasma; Saliva; Salivette(®)